Program
tirbanibulin
Also written as “KX2-391”, “Tirbanibulin ointment 1%” and “KX01 ointment 1%”.
Its studies are mostly in Keratosis, Actinic · Warts · Psoriasis · Prostatic Neoplasms · Dermatitis, Phototoxic, led by 5 companies.
Drug pageTirbanibulin: every studyMany companies study it; this page follows only the 12 they lead. All 18 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Almirall | 41 open or running | phase 4since May 19, 2022 | Mar 1, 2022 | Jul 2027phase 4 · NCT05387525 |
| Athenexits history only | 30 open or running | phase 2since Feb 22, 2010 | Jan 15, 2008 | none ahead |
| PharmaEssentiaits history only | 30 open or running | phase 3since Jan 28, 2022 | Dec 30, 2021 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 2since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| The Skin Center Dermatology Groupits history only | 10 open or running | phase 4since Jan 19, 2025 | Jan 19, 2025 | none ahead |
Also a collaborator on its studies: PharmaEssentia Japan.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Almirall only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named tirbanibulinINNProposed as its International Nonproprietary Name in WHO's List 119 · before, KX2-391
- Mar 1, 2022First study: phase 3 study in Keratosis, ActinicFirst studyNCT05279131 · 105 enrolled · United States
- May 19, 2022Phase 4 study in Keratosis, ActinicNCT05387525 · 447 enrolled · France, Germany, Italy and more
- Feb 14, 2023Phase 4 study in Keratosis, ActinicNCT05741294 · 334 enrolled · Italy, Spain
- Nov 13, 2023Phase 3 study in Keratosis, ActinicNCT06135415 · 280 enrolled · Germany, Italy, Netherlands and more
Ahead
- Jul 2027Primary completion: phase 4 study in Keratosis, ActinicNCT05387525
TargetBeta
“Tyrosine-protein kinase SRC inhibitor”ChEMBL 37, by rule
Other programs on SRC
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| SRC/YES1 Kinase Inhibitor NXP900rule | nuvectis-pharma-inc | phase 1 | 3 |
Studies
All 4 Almirall leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06135415Keratosis, Actinic · Germany, Italy, Netherlands and more | 3 | Completed | Apr 30, 2025 | 280 |
| NCT05741294Keratosis, Actinic · Italy, Spain | 4 | Completed | Jan 19, 2024 | 334 |
| NCT05387525Keratosis, Actinic · France, Germany, Italy and more | 4 | Active, not recruiting | Jul 2027 | 447 |
| NCT05279131Keratosis, Actinic · United States | 3 | Completed | Dec 28, 2022 | 105 |
How it is read
Names in the registry
- “KX2-391”, 3 entries
- “Tirbanibulin ointment 1%”, 2 entries
- “KX01 ointment 1%”, 2 entries
- “Tirbanibulin”, 1 entry
- “KX01 0.01% (0.1 mg/g)”, 1 entry
Conditions, from the studies’ own filings
- Keratosis, Actinic, 5 studies
- Warts, 1 study
- Psoriasis, 1 study
- Prostatic Neoplasms, 1 study
- Dermatitis, Phototoxic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.